2020
Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology
Billmire D, Dicken B, Rescorla F, Ross J, Piao J, Huang L, Krailo M, Pashankar F, Frazier L, Group C. Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology. Journal Of Pediatric And Adolescent Gynecology 2020, 34: 383-386. PMID: 33316416, PMCID: PMC8096645, DOI: 10.1016/j.jpag.2020.11.014.Peer-Reviewed Original ResearchConceptsMalignant ovarian germ cell tumorsMalignant germ cell tumorsGerm cell tumorsOvarian germ cell tumorsCell tumorsOncology GroupMalignant histologyImaging appearancesExtracranial malignant germ cell tumorsNonseminomatous malignant germ cell tumorsOvarian malignant germ cell tumorsSolid appearanceComplete surgical stagingElement of teratomaPediatric ovarian neoplasmsPreoperative serum markersChildren's Oncology GroupPrimary ovarian tumorsYolk sac tumorYears of ageAssociated teratomaTeratoma elementsSurgical stagingMixed histologyMulticenter trial
2016
Detection of Occult Micrometastases in Patients With Clinical Stage I Non–Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance)
Martin LW, D'Cunha J, Wang X, Herzan D, Gu L, Abraham N, Demmy TL, Detterbeck FC, Groth SS, Harpole DH, Krasna MJ, Kernstine K, Kohman LJ, Patterson GA, Sugarbaker DJ, Vollmer RT, Maddaus MA, Kratzke RA. Detection of Occult Micrometastases in Patients With Clinical Stage I Non–Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). Journal Of Clinical Oncology 2016, 34: 1484-1491. PMID: 26926677, PMCID: PMC4872306, DOI: 10.1200/jco.2015.63.4543.Peer-Reviewed Original ResearchConceptsN2 lymph nodesStage I NSCLCDisease-free survivalOccult micrometastasesLymph nodesCell lung cancerOverall survivalLung cancerStage IClinical stage I NSCLCPathologic stage I NSCLCComplete surgical stagingClinical stage IRT-PCRDecreased overall survivalNegative lymph nodesWorse survival rateSquamous cell carcinomaReal-time reverse transcriptase-polymerase chain reactionMulti-institutional trialReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionWarrants further investigationSurgical stagingPrognostic significance
2015
Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics
Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics. Gynecologic And Obstetric Investigation 2015, 81: 169-173. PMID: 26067608, DOI: 10.1159/000431219.Peer-Reviewed Original ResearchMucinous tumorsSeromucinous tumorsOvarian tumorsComplete surgical stagingNormal-appearing appendixBorderline ovarian tumorsLymph node involvementRetrospective cohort analysisRisk of recurrenceAggressive stagingNodal diseaseSurgical stagingHazard ratioNode involvementDisease recurrencePseudomyxoma peritoneiSerous tumorsSingle institutionPathology reportsCohort analysisLower riskRecurrenceMultivariate analysisFrozen sectionsTumors
2005
Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy
Kelly MG, O'Malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecologic Oncology 2005, 98: 353-359. PMID: 16005947, DOI: 10.1016/j.ygyno.2005.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleChemotherapy, AdjuvantCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDilatation and CurettageDisease-Free SurvivalFemaleHumansHysterectomyNeoplasm StagingOrganoplatinum CompoundsRetrospective StudiesUterine NeoplasmsConceptsUterine papillary serous carcinomaPlatinum-based chemotherapyResidual uterine diseaseStage IA patientsVaginal cuff radiationAdjuvant platinum-based chemotherapySurgical stage IPapillary serous carcinomaIA patientsUterine diseaseStage IHysterectomy specimenOverall survivalSerous carcinomaConcomitant platinum-based chemotherapyImproved disease-free survivalComplete surgical stagingStage IB patientsStage IC patientsDisease-free survivalHigh recurrence rateVaginal radiationAdjuvant therapyStage IASurgical staging
2004
Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation
Kelly MG, O'Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, Azodi M, Chambers SK, Schwartz PE. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecologic Oncology 2004, 95: 469-473. PMID: 15581948, DOI: 10.1016/j.ygyno.2004.08.030.Peer-Reviewed Original ResearchConceptsUterine papillary serous carcinomaStage IA patientsResidual uterine diseaseAdvanced stage uterine papillary serous carcinomaIA patientsUterine diseaseSerous cancerUterine papillary serous cancerComplete surgical stagingObstetrics stage IAPapillary serous cancerDifferent therapeutic optionsPapillary serous carcinomaPlatinum-based chemoradiationMore effective treatmentsLocoregional diseaseHysterectomy specimenStage IAStage IIIAStage IIICSurgical stagingExtrauterine metastasesSerous carcinomaTherapeutic optionsFallopian tube
1998
Effective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy
Turner B, Knisely J, Kacinski B, Haffty B, Gumbs A, Roberts K, Frank A, Peschel R, Rutherford T, Edraki B, Kohorn E, Chambers S, Schwartz P, Wilson L. Effective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 1998, 40: 77-84. PMID: 9422561, DOI: 10.1016/s0360-3016(97)00581-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyChemotherapy, AdjuvantCystadenocarcinoma, PapillaryDisease-Free SurvivalFemaleHumansHysterectomyMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesSalvage TherapyUterine NeoplasmsConceptsUterine papillary serous carcinomaWhole pelvic radiation therapyWhole-abdomen radiation therapyComplete surgical stagingDisease-free survivalActuarial disease-free survivalFIGO stage IPapillary serous carcinomaSurgical stagingActuarial OSOverall survivalSalvage rateStage IRadiation therapyUPSC patientsVaginal brachytherapyMyometrial invasionSerous carcinomaLDR brachytherapyRadiation Therapy Oncology Group (RTOG) grade 1DFS of patientsPara-aortic lymph node samplingConventional external beam radiotherapyFIGO stage IARTOG grade 3
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply